Developing groundbreaking new therapies for recurrent and metastasizing cancers by targeting the sortilin pathway.
We are developing sortilin antagonistic small molecules, which can reduce the activity and expansion of treatment resistant cancer stem cells which are the leading cause for recurrent and metastatic cancer.
Sortina Pharma´s mission is to develop effective first in class pharmacotherapy for cancer patients with or at risk of having recurrent and metastatic cancer.
With this new therapy, patients will achieve a reduced recurrence and spreading of cancer and increased survival. The company is developing sortilin antagonistic small molecules, which can reduce the activity and expansion of treatment resistant cancer stem cells which are the leading cause for recurrent and metastatic cancer.
